- Home
- AXL vs MLYS Comparison
AXL vs MLYS Comparison
Compare AXL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- MLYS
- Stock Information
- Founded
- AXL 1994
- MLYS 2019
- Country
- AXL United States
- MLYS United States
- Employees
- AXL N/A
- MLYS N/A
- Industry
- AXL Auto Parts:O.E.M.
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- AXL Consumer Discretionary
- MLYS Health Care
- Exchange
- AXL Nasdaq
- MLYS Nasdaq
- Market Cap
- AXL 576.1M
- MLYS 510.6M
- IPO Year
- AXL 1999
- MLYS 2023
- Fundamental
- Price
- AXL $5.61
- MLYS $9.56
- Analyst Decision
- AXL Hold
- MLYS Strong Buy
- Analyst Count
- AXL 6
- MLYS 2
- Target Price
- AXL $6.75
- MLYS $27.00
- AVG Volume (30 Days)
- AXL 2.9M
- MLYS 292.0K
- Earning Date
- AXL 02-14-2025
- MLYS 02-12-2025
- Dividend Yield
- AXL N/A
- MLYS N/A
- EPS Growth
- AXL N/A
- MLYS N/A
- EPS
- AXL 0.29
- MLYS N/A
- Revenue
- AXL $6,124,900,000.00
- MLYS N/A
- Revenue This Year
- AXL N/A
- MLYS N/A
- Revenue Next Year
- AXL N/A
- MLYS N/A
- P/E Ratio
- AXL $19.47
- MLYS N/A
- Revenue Growth
- AXL 0.75
- MLYS N/A
- 52 Week Low
- AXL $4.70
- MLYS $8.58
- 52 Week High
- AXL $7.98
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- AXL 53.34
- MLYS 42.42
- Support Level
- AXL $4.70
- MLYS $8.98
- Resistance Level
- AXL $5.93
- MLYS $10.75
- Average True Range (ATR)
- AXL 0.24
- MLYS 0.72
- MACD
- AXL 0.11
- MLYS 0.02
- Stochastic Oscillator
- AXL 72.40
- MLYS 27.49
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.